^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Bowens Disease |
| Drug: | Zyclara (imiquimod) (TLR8 agonist, TLR7 agonist) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
07/14/2020
Excerpt:
The NCCN panel discussed the use of alternative therapies for first-line treatment in patients with SCC in situ (Bowen’s disease)...alternative therapies the panel recommends considering include 5-FU, imiquimod…
